GERMANTOWN, Maryland and HILDEN, Germany, January 11, 2011 - QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

GERMANTOWN, Maryland and DES PLAINES, Illinois, October 12, 2010 - QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Abbott (ABT: NYSE) today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada.

VENLO, The Netherlands, February 8 - QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays.

VENLO, Netherlands - QIAGEN donates one million tests to expand access to HPV screening in the world's poorest countries Results from an eight-year trial involving more than 130,000 women published today in The New England Journal of Medicine (NEJM) demonstrate that in low-resource settings a single round of HPV testing significantly reduces the numbers of advanced cervical cancers and deaths, compared with Pap (cytology) testing or visual inspection with acetic acid (VIA).
Older News
26 27 28 29 30 31 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
Copyright© 2011 The Gaea Times